| [1] |
Zheng Y, Fu Y, Zhong Q, et al. The treatment of advanced pulmonary sarcomatoid carcinoma[J].Future Oncol,2022,18(6): 727-738. DOI:10.2217/fon-2021-1071. |
| [2] |
Gong C, Xiong H, Qin K, et al. MET alterations in advanced pulmonary sarcomatoid carcinoma[J].Front Oncol,2022,12: 1017026. DOI:10.3389/fonc.2022.1017026. |
| [3] |
Yuan M, Zhu Z, Mao W, et al. Anlotinib combined with anti-PD-1 antibodies therapy in patients with advanced refractory solid tumors: a single-center, observational, prospective study[J].Front Oncol,2021,11: 683502. DOI:10.3389/fonc.2021.683502. |
| [4] |
Zombori-Tóth N, Kiss S, Oštarijaš E, et al. Adjuvant chemotherapy could improve the survival of pulmonary sarcomatoid carcinoma: a systematic review and meta-analysis[J].Surg Oncol,2022,44: 101824. DOI:10.1016/j.suronc.2022.101824. |
| [5] |
Ma Y, Li W, Li Z, et al. Immunophenotyping of pulmonary sarcomatoid carcinoma[J].Front Immunol,2022,13: 976739. DOI:10.3389/fimmu.2022.976739. |
